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INTRODUCTION
Systemic sclerosis (SSc) is a rheumatic autoimmune disease 
of unknown etiology, clinically characterized by a vasculo-
pathy of the small and microcirculation as well as excessive 
deposition of collagen in the skin and internal organs affecting 
particularly the gastrointestinal tract, lungs, heart, and kidneys.1 
Vascular involvement is an early manifestation and represents 
a central event in the pathogenesis of the disease.2 Functional 
abnormalities and structural alterations of the blood vessels, 
including alterations in the control of vascular tonus, endo-
thelial lesion and disfunction, intimal proliferation of small 
arteries and arterioles, and diminution of the vessel’s lumen, 
can be clinically expressed in many forms such as Raynaud’s 
phenomenon, digital ischemia, sclerodermic renal crisis and 
pulmonary hypertension.2-4
ABSTRACT
Introduction: Vasculopathy is a hallmark of systemic sclerosis (SSc) and may lead to complications such as ischemic 
ulcers, necrosis or amputation of fingers or lower limbs. Bosentan is a dual endothelin receptor antagonist currently used 
for prevention of digital ulcers in SSc. Objective: To evaluate the efficacy of bosentan in the treatment of recurrent and 
refractory extremity ulcers in patients with SSc. Patients and methods: An open and observational study was performed 
with three patients from the Rheumatology Division of UNIFESP aged 31, 58 and 61 years with diagnosis of SSc. All 
patients presented one or more active extremity ulcer refractory to conventional treatment. The first one (P1) presented 
one digital ulcer; P2 presented three ulcers on the right lower limb; and P3 presented an ulcer on the right digit, leg and 
heel, and on left maleolar region. Bosentan was prescribed in a dose regimen of 62.5 mg twice a day for 4 weeks, followed 
by 125 mg twice a day for additional 4 or 8 weeks. All patients were evaluated regarding the number and diameter of the 
ulcers in weeks 0, 4, and 8, and one of them in week 12 as well. Results: After the treatment with bosentan all patients 
presented complete resolution or reduction in the diameter of the ulcers. None of the patients presented a new ulcer. 
Conclusion: Bosentan was an effective treatment in refractory extremities ulcers and in the prevention of new ulcers in 
three SSc patients suggesting that this medication could be an option for patients with severe vascular involvement.
Keywords: systemic sclerosis, Raynaud´s phenomenon, ischemic ulcers, endothelin, bosentan.
Raynaud’s phenomenon is the most frequent manifestation 
of SSc. It is characterized by transitory episodes of limb 
vasoconstriction, generally after contact with the cold or 
emotional stress, which triggers typical alterations in the 
colour of hands and/or feet. Due to the vascular abnormalities 
present in SSc, Raynaud’s phenomenon episodes are usually 
more severe in these individuals and can lead to important 
complications like ischemic ulcers of the digits and lower 
limbs. Most times ulcers are recurring, extremely painful and 
disabling, and can evolve with secondary infection, gangrene 
and even amputation of extremities.5 Many treatments are 
available for the prevention or healing of ischemic ulcers 
secondary to SSc, but most of them have little effectiveness.6-7 
The treatment of ischemic ulcers in patients with SSc involves 
nonmedicamentous measures, such as bandages and change 
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of habits (quit smoking, avoid exposure to the cold etc.), 
treatment of local infections and use of analgesics for pain 
control.8 Vasoactive drugs such as calcium channel blockers 
(nifedipin), 5-phosphodiesterase inhibitors (sildenafil), and 
prostacyclin analogs intravenously (epoprostenol, alprostadil, 
and iloprost) have shown to be effective in some patients.8-10 
Prostacyclin analogs seem to be the most effective medicine, 
but they are still not much available and have the disadvantage 
of intravenous administration and necessity of hospitalization. 
Prostacyclin analogs with oral preparation did not show to be 
effective for treatment of Raynaud’s phenomenon.4,11 
In spite of being multifactorial, endothelin-1 (ET1) has 
been more recently considered as an important factor in SSc’s 
pathogenesis.12 ET1 is a potent vasoconstrictor produced mainly 
by endothelial cells, whose serum concentrations are increased 
in patients with SSc.12-14 It is activated when connected to its 
receptors (ETA and ETB), expressed mainly by endothelial cells, 
smooth muscular cells and fibroblasts. Besides having a potent 
vasoconstrictive action, ET1 also stimulates the proliferation 
of fibroblasts and smooth muscular cells.14 Bosentan is an oral 
dual endothelin receptor antagonist used in the treatment of 
idiopathic pulmonary hypertension or secondary to autoimmune 
rheumatic diseases, including SSc.15 More recent studies showed 
that the drug can also be beneficial for treatment of patients 
with ischemic ulcers secondary to SSc.5,16-18 Two multicentric, 
placebo-controlled, double-blind studies (RAPIDS-1 and 
RAPIDS-2) were performed with a great number of patients 
to evaluate the effectiveness of bosentan in the treatment and 
prevention of acute ischemic ulcers in patients with SSc.5,16 
The RAPIDS-1 study showed that bosentan was effective in 
the prevention of new digital ulcers (mean 48% less than the 
placebo group). It was not demonstrated that bosentan reduced 
the period of healing of active ulcers (secondary endpoint). 
RAPIDS-2 was a study involving a larger number of patients 
that confirmed the findings of RAPIDS-1 regarding the 
prevention of new ulcers.
Due to the lack of studies about this therapeutic modality 
in our environment, we performed an open, observational 
study, for the evaluation of bosentan’s effectiveness in a small 
group of SSc patients with recurring ulcers that are refractory 
to conventional treatments.
PATIENTS AND METHODS
Three patients from the Systemic Sclerosis Division of Rheu-
matology at Hospital São Paulo (UNIFESP) diagnosed with 
SSc according to the American College of Rheumatology 
(ACR)19 criteria were included. All patients agreed to partici-
pate in the study and signed the Informed Consent Form, pre-
viously approved by the Ethics Committee of UNIFESP. They 
all presented complaints of important Raynaud’s phenomenon, 
recurring ulcers and one or more active limb ulcers, which had 
not responded to the treatment with conventional drugs. 
The clinical and demographic characteristics of the three 
patients are described in Table 1. Patient P1 presented a digital 
ulcer in the right hand (A); patient P2 presented three ulcers 
in the right lower limb (A, B, C); patient P3 presented ulcers 
in right digit (A), leg (B), and heel (C), and left malleolo (D) 
(Table 2). Patient P1, age 31, presented the diffuse cutaneous 
form of SSc overlapping with systemic lupus erythematosus for 
Table 1
Clinical and demographic characteristics of the patients treated with bosentan
Characteristics Patient 1 Patient 2 Patient 3
Age (years) 31 58 61
Gender F F F
Time of diagnosis 9 years 12 years 6 years
Disease form (limited/diffuse) Diffuse Diffuse Limited
Number of ulcers active at the beginning of the treatment 1 3 4
Antinuclear antibodies research (ANA) Nuclear dense speckled 1/320 Nuclear fine speckled 1/320 Nuclear centromeric 1/1280
Anti-Scl 70 Negative Positive Negative
Periungueal capillaroscopy Pattern SD Pattern SD Pattern SD
Cutaneous score of Rodnan 19 33 17
Other medication used for RP during treatment Nifedipin Captopril Nifedipin and Losartan AAS 
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9 years, and also an extremely painful ulcer for approximately 
8 weeks in the third digit of the right hand. The patient had 
already suffered previous amputation of the fourth digit and 
important loss of substance in the second right digit by ulcer. 
She was using: nifedipin 20 mg, 8/8h, and captopril 12,5 mg, 
12/12h. Patient P2, age 58, had the diffuse cutaneous form of 
SSc for 12 years and had presented three ulcers in her lower 
right limb (pretibial and malleolar regions) for approximately 
1 year. During this period she used: nifedipin 20 mg, 8/8h, 
losartan 100 mg/day, diltiazen 30 mg, 8/8h, pentoxifylline 400 
mg, 12/12h, tramadol 50 mg, 8/8 h, intravenous xylocaine, 
besides local care (bandages in ulcers clinic), without any 
results. She kept using nifedipin 20 mg, 8/8h, in the 0 week. 
Patient P3, age 61, with the limited form of SSc for 6 years, 
presented an ulcer in the lateral region of the right leg and in 
the left malleolar region for approximately 1 year and an ulcer 
in the right second digit and heel for approximately 6 weeks. 
She had used: captopril 50 mg, 8/8h, nifedipin 20 mg, 6/6h, 
tramadol 50 mg, 8/8h, and AAS 100 mg/d, besides courses 
of antibiotics for the associated infection, also without any 
results. She did not tolerate the use of captopril or nifedipin 
due to hypotension.
TREATMENT AND EVALUATION PROTOCOL
Bosentan (kindly supplied by Actelion Pharmaceuticals do 
Brasil) was administered in the dosage of 62,5 mg VO two 
times/day for 4 weeks, followed by 125 mg two times/day for 
more 4 or 8 weeks. Other medications used by the patients 
were kept.
Patients were evaluated by the same researcher as to the 
number of ulcers and their diameter (in millimeters), in the 0, 
4, and 8 weeks, and patient P3, who presented a more severe 
onset (four ulcers), was also evaluated after 12 weeks. In each 
evaluation, the patients were also questioned about the severity 
of Raynaud’s phenomenon in the last week with visual analog 
scale of severity (grading from 0 to 10, where 0 means absence 
of Raynaud’s phenomenon episodes, and 10 means the worst 
episodes experienced by the patient), and regarding the pain 
intensity of Raynaud’s phenomenon with a visual analog pain 
scale (grading from 0 to 10, where 0 means no pain, and 10 
means extreme pain). 
During the study, transaminases was verified, before, and 
with 4 and 8 weeks of treatment, for monitoring the appearance 
of medicamentous hepatitis.
RESULTS
After the treatment with bosentan all patients presented healing 
or reduction in the diameter of the ulcers (Table 2). Patients 
P1 and P2 presented complete cicatrization of the ulcers, and 
patient P3 presented cicatrization of the two smaller ulcers and 
important reduction in the diameter of the larger ulcers (Figure 
1). None of the patients presented new ulcers, or alteration 
in the transaminases levels before and after the treatment. 
After eight weeks of treatment, a heterogeneous behavior 
was observed regarding the visual analog scales of severity of 
Raynaud’s phenomenon and pain intensity (Figure 2). Patient 
P3 presented an important improvement in the intensity of the 
pain and severity of Raynaud’s phenomenon followed by a new 
worsening, due to a cyanosis in the second right pododactile, 
without ulceration.
DISCUSSION
Ischemic ulcers represent a severe and extremely disabling 
manifestation which affects up to 50% of the patients with 
SSc.20 In the present study, we observed an improvement and 
fast cicatrization of ischemic ulcers in the three patients with 
SSc who used bosentan for 8 or 12 weeks. We highlight that all 
Table 2
Evolution of the diameter (millimeters) of ulcers after treatment with bosentan in patients with systemic sclerosis
Ulcers
Time
P1 P2 P3
A A B  C A B C D
Day 0 9 x 7 15 x 8 10 x 5 21 x 14 9 x 4 45 x 30 15 x 15 10 x 10
Week 4 8 x 8 * * 15 x 12 * 40 x 28 15 x 21 15 x 10
Week 8 * * * * * 40 x 25 17 x 20 12 x 12
Week 12 – – – – * 20 x 17 3 x 2 *
* Ulcers which healed entirely.
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Figure 1. Digital ulcer of the right hand in patient P1 before treatment with bosentan (A) and after 4 weeks (B). Ulcer in right lower limb of patient P3 before treatment 
with bosentan (C) and after 12 weeks (D).
A
C
B
D
Figure 2. Evolution of the visual analog severity scale (A) of Raynaud’s phenomenon and visual analog pain scale (B) during the follow-up of the three patients.
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patients presented important peripheral vasculopathy – patient 
P1 presented a previous amputation of one digit, and patients 
P2 and P3 presented ulcers in lower limbs for approximately 
one year, all nonresponsive to treatment with calcium channel 
blockers, normally used as the first drug of choice in our servi-
ce. Due to its ischemic characteristics, the ulcers secondary to 
SSc are usually extremely painful. We observed a significant 
improvement in the visual analog pain scale in two of the three 
patients evaluated.
Based on the results of the RAPIDS-1 and RAPIDS-2 
studies, bosentan is a therapy approved in Europe for the 
reduction of the number of new ulcers in patients with 
SSc. Besides that, Peña-Lefebvre et al.18 recently published 
a prospective study that evaluated the effectiveness and 
tolerability of bosentan in patients with SSc in the long term. 
There was a significant decrease in the number of new ulcers 
and a tendency to a decrease in the number of healed ulcers. 
Nevertheless, many questions regarding the role of bosentan 
in the treatment of ischemic ulcers have yet to be clarified, 
like which patients should be treated and at which moment. 
As the RAPIDS-1 and RAPIDS-2 studies showed that the 
treatment with bosentan is more preventive than curative, 
a questioning that emerges is if the drug should be used 
in patients with vasculopathy before becoming refractory, 
which would aim at decreasing severe complications such as 
gangrene and limb amputations. We should also remember 
that the cost of the medicine is high and it should be suggested 
only in selected cases. 
Besides the vascular component, other factors associated 
with the presence of ulcers, mainly digital ulcers, are dermis 
fibrosis, dry and atrophic skin, micro traumas, and articular 
contractures.6 These factors are implied in the poor response 
that some ulcers present facing therapies with vasodilators8 and 
were also implied by Korn et al. as one of the possible factors 
which justify the negative results obtained in the cicatrization 
of digital ulcers in the RAPIDS-1 study.5 The fact that the two 
patients with ulcers in the lower limbs presented a relatively 
fast cicatrization makes us believe that such ulcers present a 
greater predominance of the vascular component or suffer a 
minor influence of factors such as local traumas, presenting 
a more satisfactory response to a potent vasodilator like 
bosentan. Another factor that may have influenced the positive 
response obtained in our study is that the ulcers were clearly 
active at the beginning of the study, and healed or partially 
healed ulcers were not included in the evaluation. Studies with 
a larger number of patients presenting this type of ulcers are 
necessary to prove such hypothesis.
This study presents some limitations such as a small number 
of evaluated patients and the fact that it is a noncontrolled study 
of short duration and should be seen more as descriptive study. 
Nevertheless, SSc is a rare and extremely disabling disease, 
and the present observation of a clear reduction in the ulcer 
diameter or cicatrization ulcers in evaluated patients shows 
to be relevant.
 In conclusion, the treatment with the endothelin receptor 
antagonist bosentan proved to be effective in the prevention of 
new ulcers in a short term and in the cicatrization of limb ulcers 
in three patients with SSc from our service. So, it is suggested 
that the drug could be a therapeutical option in patients with 
severe vasculopathy.
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